FDA Accepts Gilead's Yeztugo Application for Once-Weekly HIV Prevention, PDUFA Set for Feb 2027
GILD sits 19% above its 52-week low of $104.46.
Summary
The U.S. FDA has accepted Gilead's Supplemental New Drug Application for Yeztugo, an investigational once-weekly oral pill for HIV prevention. This marks a significant regulatory milestone for a drug that could become the first long-acting oral option for HIV pre-exposure prophylaxis. The acceptance moves Yeztugo closer to potential market approval, strengthening Gilead's pipeline and future revenue prospects in the critical HIV treatment and prevention market. The PDUFA date for a decision is set for February 2, 2027.
At the time of this announcement, GILD was trading at $124.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154.3B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.